BI 655130

Drug Profile

BI 655130

Alternative Names: BI655130

Latest Information Update: 23 Jan 2017

Price : $50

At a glance

  • Originator Boehringer Ingelheim
  • Class Antipsoriatics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Pustular psoriasis

Most Recent Events

  • 01 Dec 2016 Phase-I clinical trials in Pustular psoriasis (Treatment-experienced) in South Korea (IV) (NCT02978690)
  • 29 Nov 2016 Boehringer Ingelheim plans a phase I trial for Pustular psoriasis (Treatment-experienced) in Taiwan, France, Japan, South Korea, Singapore, Malaysia and Tunisia (IV) (NCT02978690)
  • 01 Aug 2016 Boehringer Ingelheim initiates a phase I trial in Healthy volunteers in Belgium (IV) (NCT02852824)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top